Your browser doesn't support javascript.
loading
A Lead-In with Silibinin Prior to Triple-Therapy Translates into Favorable Treatment Outcomes in Difficult-To-Treat HIV/Hepatitis C Coinfected Patients.
Braun, Dominique L; Rauch, Andri; Aouri, Manel; Durisch, Nina; Eberhard, Nadia; Anagnostopoulos, Alexia; Ledergerber, Bruno; Müllhaupt, Beat; Metzner, Karin J; Decosterd, Laurent; Böni, Jürg; Weber, Rainer; Fehr, Jan.
Afiliación
  • Braun DL; Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland; Institute of Medical Virology, University of Zurich, Zurich, Switzerland.
  • Rauch A; Department of Infectious Diseases, Bern University Hospital and University of Bern, Bern, Switzerland.
  • Aouri M; Division of Clinical Pharmacology, University Hospital Center, University of Lausanne, Lausanne, Switzerland.
  • Durisch N; Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
  • Eberhard N; Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
  • Anagnostopoulos A; Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
  • Ledergerber B; Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
  • Müllhaupt B; Clinic for Gastroenterology and Hepatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
  • Metzner KJ; Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland; Institute of Medical Virology, University of Zurich, Zurich, Switzerland.
  • Decosterd L; Division of Clinical Pharmacology, University Hospital Center, University of Lausanne, Lausanne, Switzerland.
  • Böni J; Swiss National Center for Retroviruses, Institute of Medical Virology, University of Zurich, Zurich, Switzerland.
  • Weber R; Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
  • Fehr J; Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
PLoS One ; 10(7): e0133028, 2015.
Article en En | MEDLINE | ID: mdl-26176696
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Métodos Terapéuticos y Terapias MTCI: Plantas_medicinales Asunto principal: Antivirales / Silimarina / ARN Viral / Infecciones por VIH / Hepatitis C Crónica / Terapia Antirretroviral Altamente Activa / Cirrosis Hepática Tipo de estudio: Observational_studies / Risk_factors_studies Idioma: En Revista: PLoS One Año: 2015 Tipo del documento: Article País de afiliación: Suiza
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Métodos Terapéuticos y Terapias MTCI: Plantas_medicinales Asunto principal: Antivirales / Silimarina / ARN Viral / Infecciones por VIH / Hepatitis C Crónica / Terapia Antirretroviral Altamente Activa / Cirrosis Hepática Tipo de estudio: Observational_studies / Risk_factors_studies Idioma: En Revista: PLoS One Año: 2015 Tipo del documento: Article País de afiliación: Suiza